Skip to search formSkip to main contentSkip to account menu

NSC-132313

Known as: NSC 132313, NSC132313 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Dianhydrogalactitol

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Effect of a single high dose and repeated small doses of dianhydrogalactitol (DAG; NSC-132313) on rat intestinal mucosa
SummaryThe influence of the treatment schedule of dianhydrogalactitol on its effect on the activity of mucosal enzymes in rat… 
1981
1981
The effect of dibromo-dulcitol and dianhydro-dulcitol (galactitol) on RNA synthesis in ascites tumor cells.
The mechanism of action on RNA synthesis of anticancer dibromo-dulcitol (DBD, NSC-104800) and dianhydro-dulcitol (DAD, or… 
1979
1979
Phase I evaluation of the combination 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) and dianhydrogalactitol (DAG; NSC-132313) in patients with advanced neoplastic diseases.
1977
1977
A preliminary Pharmacokinetic study of dianhydrogalactitol (NSC-132313) disposition in the dog.
The pharmacokinetics of dianhydrogalactitol (DAG), NSC-132313, were studied in the beagle dog at doses of 3 mg - kg-1 and 6 mg… 
1977
1977
Cell killing, kinetics, and recovery responses induced by 1,2:5,6-dianhydrogalactitol in dividing and nondividiing cells in vitro.
The survival and cell kinetics effect of 1,2:5,6-dianhydrogalactitol, NSC-132313 (galactitol), were studied on mammalian cells… 
1976
1976
Phase I evaluation of dianhydrogalactitol (NSC-132313).
A toxicologic evaluation of dianhydrogalactitol in man was completed for a 5- and a 10-day schedule. The maximum tolerated dose… 
1976
1976
Phase I study of a five-day intermittent schedule for 1,2:5,6-dianhydrogalactitol (NSC-132313).
Because 1,2:5,6-dianhydrogalactitol (NSC-132313 (DAG; the main conversion reaction product of the treatment of dibromodulcitol by… 
1976
1976
Dianhydrogalactitol (NSC-132313): pharmacokinetics in normal and tumor-bearing rat brain and antitumor activity against three intracerebral rodent tumors.
Dianhydrogalactitol (DAG; NSC-132313), a hexitol epoxide, was used to treat intracerebral rodent tumors. DAG was most active… 
1975
1975
Survival and phase sensitivity of HeLa cells treated with dianhydrogalactitol (NSC-132313).
The effect of dianhydrogalactitol on survival and phase sensitivity of the cell cycle of HeLa cells was studied. In survival… 
1972
1972
Pharmacologic and antitumor effects of 1,2:5,6-dianhydrogalactitol (NSC-132313).
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)